Research analysts at StockNews.com began coverage on shares of Minerva Neurosciences (NASDAQ:NERV – Get Free Report) in a research note issued to investors on Wednesday. The firm set a “sell” rating on the biopharmaceutical company’s stock.
Separately, HC Wainwright lowered their target price on shares of Minerva Neurosciences from $7.00 to $5.00 and set a “neutral” rating for the company in a research note on Wednesday, August 7th.
Read Our Latest Report on Minerva Neurosciences
Minerva Neurosciences Price Performance
Minerva Neurosciences (NASDAQ:NERV – Get Free Report) last issued its quarterly earnings data on Tuesday, August 6th. The biopharmaceutical company reported ($1.09) earnings per share for the quarter, missing the consensus estimate of ($0.97) by ($0.12). Sell-side analysts forecast that Minerva Neurosciences will post -2.26 EPS for the current year.
About Minerva Neurosciences
Minerva Neurosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders.
Further Reading
- Five stocks we like better than Minerva Neurosciences
- Using the MarketBeat Dividend Yield Calculator
- NVIDIA’s AI Dominance: Why Analysts Predict Major Upside Ahead
- Bank Stocks – Best Bank Stocks to Invest In
- These Stocks Are Using Buybacks to Unlock Big Gains for Investors
- Investing in Travel Stocks Benefits
- This Is the Entry Into PepsiCo You’ve Been Waiting For
Receive News & Ratings for Minerva Neurosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Minerva Neurosciences and related companies with MarketBeat.com's FREE daily email newsletter.